human immune globulin IV 10% (IVIG) / Liminal BioSci - LARVOL DELTA

IGIV: Safety, Tolerability, Efficacy, and Pharmacokinetic Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% (clinicaltrials.gov) - P3; N=82; Active, not recruiting; Sponsor: Prometic Biotherapeutics, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: May 2018 ➔ Feb 2019; Trial primary completion date: Mar 2018 ➔ Feb 2019

Clinical • Enrollment closed • Trial completion date • Trial primary completion date